Cancers, Vol. 12, Pages 1488: First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

Conclusion: tTF-NGR is safely applicable with this regimen. Imaging showed selective reduction of tumor blood flow and intratumoral hemorrhage and necrosis.

Source: Cancers - June 6, 2020 Category: Cancer & Oncology Authors: Christoph Schliemann Mirjam Gerwing Hauke Heinzow Saliha Harrach Christian Schw öppe Moritz Wildgruber Anna A. Hansmeier Linus Angenendt Andrew F. Berdel Ursula Stalmann Bj örna Berning Karsten Kratz-Albers Kristina Middelberg-Bisping Stefanie Wiebe J à Tags: Article Source Type: research